A total of 4033 patients scheduled for coronary angiography were randomized to receive pretreatment with prasugrel or no prasugrel. There were no significant differences in the primary endpoint ...

But the new drug, prasugrel (Effient), is also more likely to cause potentially fatal bleeding. Overall, prasugrel may be superior to the approved dose of the older drug, clopidogrel (Plavix), in ...

Also limiting that population could be the recommendations from the panel that prasugrel, to be marketed under the name Effient, not be given to patients over 75 years old or with a history of ...

INDIANAPOLIS and TOKYO, Aug. 15, 2011 /PRNewswire/ -- A new post-hoc sub-analysis of an important set of patients from the TRITON-TIMI 38 study – those identified as the "core clinical cohort ...

July 11 -- FRIDAY, July 10 (HealthDay News) -- The U.S. Food and Drug Administration has approved the Eli Lilly blood-thinner Effient (prasugrel) to prevent clots in people who have an artery ...

EFFIENT (prasugrel) 5mg, 10mg tablets by Daiichi Sankyo and Eli Lilly Effient (prasugrel tablets, from Daiichi Sankyo and Eli Lilly), a platelet aggregation inhibitor, is now available for the ...

PCI usually includes the placement of a stent to help keep the artery open. Effient® (prasugrel) can cause bleeding. If patients have unexplained or excessive bleeding while on Effient ...

EFFIENT (prasugrel) 5mg, 10mg tablets by Daiichi Sankyo and Eli Lilly The FDA has approved Effient (prasugrel tablets, from Daiichi Sankyo and Eli Lilly), a platelet aggregation inhibitor ...

A randomized, head-to-head comparison of prasugrel (Effient; Eli Lilly) and ticagrelor (Brilinta; AstraZeneca) had never been performed, leaving it up to physician discretion which drug to choose.

The FDA's approval of Eli Lilly's new blood-thinner, Effient/prasugrel, was a huge moment for a company that has not had a new drug approved in five years. But Wall Street's analysts seem ...

Indianapolis and Tokyo -- A new post-hoc sub-analysis of an important set of patients from the TRITON-TIMI 38 study – those identified as the "core clinical cohort" population – showed that treatment ...